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Acute-on-chronic liver failure (ACLF) is a newly recognized
syndrome associatedwith a highmortality. The prevalence of
ACLF is around 30% among patients hospitalized with acute
decompensation; it is more frequent in alcoholic- and hepa-
titis-B-associated cirrhosis.1 Clinical course and number of
organ failures are the most relevant factors associated with
ACLF-related mortality, irrespective of triggering factors.2
We report a case of a patient admitted with acute decom-
pensation secondary to infection and/or severe acute alco-
holic hepatitis (AAH), who developed ACLF-1 during
hospitalization. The patient was successfully treated with
an antibiotic and steroid course in sequence.
Case Presentation
A 48-year-old man, showing a compensated alcohol-related
cirrhosis since 2011 (Child-Pugh A5), was admitted to the
hospital in October 2015 because of jaundice and unspecific
abdominal pain. His alcohol intake exceeded 80 g/d until
2009; it had decreased to 40 g/d at the time of the admission.
In 2012, he underwent an upper endoscopy, which detected
small esophageal varices. The patient had neither previous
complications of cirrhosis nor current treatment. One week
prior to the admission, he had had cough and fever (up to
40°C), and was treated with acetaminophen 500 mg 3 times
per day. The patient denied changing the pattern of alcohol
consumption or taking illicit or recreational drugs. Physical
examination revealed jaundice, spiders on the trunk, and no
signs of hepatic encephalopathy, clinical ascites, or edema.
Vital signs, including peripheral capillary oxygen saturation
(98%) and blood pressure (135/65 mm Hg), were normal.
Laboratory tests showed a high total bilirubin (TB) level
(25.41 mg/dL) with typical alcohol-related liver enzymes
values (alanine aminotransferase 80 IU/mL, alanine amino-
transferase 40 IU/mL), as well as international normalized
ratio (1.53) and platelet count (97  109/L) linked to ad-
vanced liver disease. By contrast, kidney functionwas normal










Abstract Acute-on-chronic liver failure (ACLF) represents a reversible syndrome associated with
high short-term mortality, characterized by acute decompensation in patients with
chronic liver disease and extrahepatic organ failure. Diagnosis and prognosis assess-
ment is based on a newly developed diagnostic score, the Chronic Liver Failure
Consortium Organ Failure score. Susceptibility to infections and systemic inflammation
are typical triggers. The authors report a case in which a patient with alcohol-related
cirrhosis was admitted to the hospital with acute decompensation and developed ACLF
during hospitalization. This case led to an evaluation of the underlying process causing
ACLF: infection versus acute alcoholic hepatitis.
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ultrasound showedminimal perihepatic ascites and the chest
X-ray a pneumonic process (►Fig. 1).
Empirical antibiotic therapy with ceftriaxone (2 g intrave-
nously [IV] once per day) and levofloxacin (500 mg IV once
per day) was started to treat pneumonia as the triggering
factor of decompensated cirrhosis (the patient did not meet
ACLF criteria) (►Fig. 2A). Pentoxifylline 400 mg orally 3 times
per day was also added to the treatment. Upper endoscopy
showed five enlarged veins, three of them with protruding
vessels, and a moderate portal hypertensive gastropathy.
Consequently, carvedilol 6.25 mg orally twice per day was
prescribed. Eleven days after admission, he was asymptom-
atic although with similar TB (21.57 mg/dL). However, hypo-
tension and an acute kidney injury (creatinine 1.75 mg/dL)
were observed. At that moment, he met ACLF-1 criteria
(►Fig. 2B). Given the temporal relation, carvedilol was with-
drawn and albumin IV was prescribed (1 g/kg/d for 3 days).
Moreover, a diagnostic paracentesis was performed, ruling
out spontaneous bacterial peritonitis (SBP). In a computed
tomography scan, a partially resolved pneumonic process
was observed after a 15-day period of antibiotic treatment
(►Fig. 3). However, there was a worsening of the overall
status, with increased abdominal pain. A glycopeptide-sus-
ceptible Enterococcus faecium was detected in an ascitic
fluid culture from the previous diagnostic paracentesis.
Therefore, the patient suffered from a symptomatic mono-
microbial nonneutrocytic bacterascites. We replaced
levofloxacin with teicoplanin 400 mg IV once per day after
consulting with the infectious diseases department (and
keeping ceftriaxone). There was an improvement in the
patient’s overall status and a normalization of kidney func-
tion after a 5-day period of ceftriaxone and teicoplanin.
Nevertheless, bilirubin levels were similar to previous days
(TB 26.82 mg/dL), so we decided to perform a transjugular
liver biopsy. Histological findings showed AAH on alcoholic
liver cirrhosis (►Fig. 4), and the hepatic venous pressure
gradient was 27 mm Hg. After normalization of kidney
function, propranolol 20 mg orally twice per day was admin-
istrated, but it had to be withdrawn because of hypotension
and a mild acute kidney injury, which resolved a few days
later (►Fig. 5A).
One month after admission and one week after the end of
treatment for both pneumonia and bacterascites, prednisone
40 mg orally once per day was added to the treatment,
according to histological AAH findings and a Maddrey score
> 32. The patient had TB 18.49 mg/dL and prothrombin time
17.6 s at the beginning of the steroid cycle. Hewas discharged
with a 1-week course of prednisone after reducing TB levels
Fig. 1 Chest X-ray showing a condensation in the left lower lobe.
Fig. 2 (A) The Chronic Liver Failure Consortium organ failure score. (B) Grades of severity of acute-on-chronic liver failure. ACLF, acute-on-chronic
liver failure; MAP, mean arterial pressure; INR, international normalized ratio; HE, hepatic encephalopathy.
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(10.25 mg/dL) (►Fig. 5B). When the patient finished a 28-day
period of treatment with prednisone 40 mg daily followed by
a 2-week taper, he developed a cellulitis affecting his right leg.
He was treated with amoxicillin-clavulanic acid (500/125 mg
orally 3 times per day for 8 days) and diuretics until resolution
(►Fig. 6). Simultaneously, laboratory testing showed a de-
crease in TB levels to 6.04 mg/dL.
Discussion
Acute-on-chronic liver failure is an increasingly recognized
entity characterized by acute deterioration in liver function in
a patient with chronic liver disease, together with organ
failure and a high short-term mortality.3 Over time, several
diagnostic criteria have been proposed for this syndrome. The
CANONIC (CLIFAcute on Chronic Liver Failure) study provided
a solid definition of the epidemiology, diagnosis, and prog-
nosis of ACLF based on prospective data to identify patients
with a 28-day mortality over 15%.4 The Chronic Liver Failure
Consortium Organ Failure (CLIF-C-OF) score, derived from
Sequential Organ Failure Assessment score criteria, deter-
mines the prognosis depending on the specific organ
involved. Thus, patients are classified as having ACLF with
three grades of severity, with an increasing risk of short-term
death from grade 1 (22%) to grade 3 (77%).5
The development of ACLF may occur at any time during
hospitalization in patients with compensated to longstanding
cirrhosis. About 10% of patients admitted with decompen-
sated cirrhosis will develop ACLF, as shown in this case report.
In fact, our patient showed only liver failure at admission,
which could not be considered ACLF. However, the patient
reached ACLF-1 when acute kidney injury presented at day
10. It has been reported that ACLF grades between the third
and seventh day after diagnosis (d3–d7 ACLF) predicted the
short- and mid-term prognosis more accurately than the
initial grade. Regarding ACLF-1, most patients will experience
the resolution of the syndrome, similar to the current clinical
case. Therefore, the dynamic nature of this syndrome should
make us be alert because patients can move rapidly from any
grade to ACLF to its resolution.
A precipitating event is frequently unnoticed and not
necessary for diagnosis. Bacterial infection is the main iden-
tified insult (33%), followed by active alcoholism.1 Among
infections, SBP, pneumonia, and urinary tract infections are
the most relevant. The pathophysiology of infection-induced
organ failure remains poorly understood, but a rapid deteri-
oration of cardiovascular function and organ perfusion, as
well as direct organ damage secondary to an exaggerated
inflammatory response appear to be essential.6 Our patient
exhibited two of the main infections (pneumonia and bacter-
ascites) typically associated with ACLF. Initially, we started
antibiotic treatment for pneumonia as the main trigger of the
acute decompensation, and, then bacterascites was properly
treated.7
The systemic inflammatory response is a typical feature of
ACLF. Thus, the increased white cell count at admission is an
independent predictor of mortality, representing a nonspe-
cific response to inflammationwhose underlyingmechanism
is unknown.8 The CLIF-C-ACLF score was designed to predict
survival, which results from a combination of three factors
independently associated with mortality: CLIF-C-OF score,
age, and white cell count. This score, by measuring both
hepatic and extrahepatic organ dysfunction, discriminates
significantly better between survivors and nonsurvivors than
does the Model of End-Stage Liver Disease (MELD) and the
Child-Pugh scoring systems, reflecting the impact of organ
failure on prognosis.9
On the other hand, the recent study by Mookerjee et al
showed that ongoing treatment with nonselective β blockers
(NSBBs)was safe and independently associatedwith improved
28-day survival by reducing the severity of ACLF and prevent-
ing its progression tomore advanced stages.10 Themechanism
appears to be related to their beneficial effects on gut motility
and permeability, reducing bacterial translocation and
systemic inflammation. However, our patient developed
ACLF-1 because of the addition of kidney injury to liver failure
Fig. 3 Chest computed tomography scan showing bilateral atelectasis and a partially resolved pneumonic process.
Seminars in Liver Disease Vol. 36 No. 2/2016
































in the setting of administration of carvedilol. This aspect
improved after NSBB withdrawal and infusion with IV
albumin.11,12
Our patient showedhigh TB levels despite an observational
period since both infectious processes were solved. Given the
concomitant presence of biopsy-proven AAH, we added
prednisone 40 mg orally to the treatment (in combination
with pentoxifylline started at admission), observing a pro-
gressive decrease in TB levels until discharge.13 Whether this
latter conditionwas the result from the steroid course or from
the time-dependent evolution of the liver failure is impossi-
ble to determine. Regarding AAH, controversy persists about
steroid use.14 In this setting, a major drawback of steroid
therapy is the increased susceptibility to infections, as con-
firmed by the lower leg cellulitis in our patient. The recent
study by Thursz et al showedmortality attributed to infection
was similar regardless of whether prednisolone was
administered.15
In conclusion, the early diagnosis and treatment of pre-
cipitating events in an enhanced or critical care environment
results in higher survival rates for patients suffering from
ACLF. However, more than one precipitant factor requiring
treatment could be noted in this entity, making the diagnosis
sometimes difficult. Acute-on-chronic liver failure is a
dynamic syndrome that can vary during the hospitalization,
requiring a routine evaluation of its presence.
Fig. 4 Liver biopsy consistent with acute alcoholic hepatitis. (A) Numerous slightly enlarged hepatocytes (ballooning) with moderate
macrovesicular fatty change (vertical arrow); several cells containing intracytoplasmic aggregates of amorphous, eosinophilic material, so-called
Mallory’s hyaline (horizontal arrow) (hematoxylin and eosin [H&E],20). (B) Occasional mild intracytoplasmic cholestasis (vertical arrow) and focal
necrosis accompanied by a mixed inflammatory cellular infiltrate with elevated number of neutrophils (horizontal arrow) (H&E, 20).
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AAH acute alcoholic hepatitis
ACLF acute-on-chronic liver failure
NSBBs nonselective beta blockers
SBP spontaneous bacterial peritonitis
TB total bilirubin
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Fig. 5 Laboratory tests during hospitalization. (A) Creatinine levels.
(B) Bilirubin levels. AAH, acute alcoholic hepatitis.
Fig. 6 Right leg cellulitis after steroids treatment (A) and after an 8-
day treatment with oral diuretics and amoxicillin-clavulanic acid (B).
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